Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8990464 | 0.67 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3ADRA1AHTR1A | |
| SCHEMBL28504288 | 0.67 | HTR2A (0.43) | SLC6A2SLC6A4SLC6A3ADRA1AHTR1A | |
| SCHEMBL3865796 | 0.66 | IDO1 (0.67) | IDO1TSHR | |
| SCHEMBL20052999 | 0.63 | TSHR (0.50) | SLC6A2SLC6A4SLC6A3HTR1AIDO1 | |
| SCHEMBL28494644 | 0.63 | IDO1 (0.34) | SLC6A2SLC6A4SLC6A3IDO1TSHR | |
| SCHEMBL28501995 | 0.62 | HTR2A (0.36) | SLC6A2SLC6A4SLC6A3ADRA1ATSHR | |
| SCHEMBL1980390 | 0.62 | ADRA1A (0.50) | SLC6A2SLC6A4SLC6A3ADRA1ANAAA | |
| SCHEMBL31065556 | 0.62 | IDO1 (0.67) | IDO1TSHR | |
| SCHEMBL2714973 | 0.62 | IDO1 (0.67) | IDO1TSHR | |
| SCHEMBL6643892 | 0.62 | TSHR (0.42) | IDO1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120189546-A1 | Radiolabelling Method Using Cycloalkyl Groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189546-A1 | Radiolabelling Method Using Cycloalkyl Groups | TMEM14C, PAICS, QPCT | SLC6A2 2038/4885SLC6A4 1851/4885SLC6A3 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.